ITMCTR2200006804尚未招募1 期
A randomized, double-blind, placebo-controlled study of the tricolor ointment for the treatment of osteoarthritic synovitis
onghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 性别
- All
入选标准
- •1.Clinical criteria: ? pain in the knee ?Crepitus on active movements ? Morning stiffness=30 min; ?Age=50 years ? swelling of knee joint; ? knee joint distension discomfort or pain; ? When the knee joint is straight or completely flexed, the feeling of distension discomfort or pain is significantly aggravated; ?palpable warmth ? Positive patellar tap test, or excessive effusion in knee joint detected by B-ultrasound or MRI; Patients with ??? and any two other conditions can be diagnosed as knee osteoarthritis synovitis.
- •?meeting the above diagnostic criteria;?Age 50-70 years;?Kellgren-Lawrence classification belongs to grade 1, 2, 3; (4) The VAS pain score was 4-7; ? Volunteer to participate in this trial, and sign the informed consent.
排除标准
- •Exclusion criteria ? women who are preparing to become pregnant or pregnant or breastfeeding; ? Allergic constitution or allergic to known components of the drug used in this test; ? Patients with knee osteoarthritis without swelling, rheumatoid arthritis, rheumatoid arthritis, infectious arthritis, gouty synovitis, synovial tuberculosis, synovioma, hemophilia arthritis, bone tumor, pigmented villonodular synovitis, osteomalacia, multiple myeloma, diabetes mellitus and other serious primary diseases; (4) Hematoma or hyperthyroidism or liver and kidney insufficiency in the knee joint cavity; ? patients with a history of drug abuse, alcoholism, mental illness or Alzheimer's disease; ? Patients who had been treated for synovitis of knee joint within 3 months before the test; ? have participated in other drug clinical trials within 3 months.
研究者
相似试验
未知
3 期
A randomized, double-blind, placebo-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long term efficacy up to 2 years in patients with active rheumatoid arthritis who have an inadequate response to anti-TNF-alpha agentsRheumatoid ArthritisJPRN-jRCT2080221561ovartis Pharma K.K.
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled study to assess the effect of Tamsulosin OCAS 0.4 mg tablets, once daily on nocturia, compared to placebo, in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia - RESTORETS (lower urinary tract symptoms) associated with BPH (benign prostatic hyperplasia)EUCTR2005-001627-11-PTYamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V., as of August 2005)1,051
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled study to assess the effect of Tamsulosin OCAS 0.4 mg tablets, once daily on nocturia, compared to placebo, in patients with lower urinary tract symptoms associated with benign prostatic hyperplasiaEUCTR2005-001627-11-ITYAMANOUCHI PHARMA882
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled study to assess the effect of Tamsulosin OCAS 0.4 mg tablets, once daily on nocturia, compared to placebo, in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia - RESTOREEUCTR2005-001627-11-FIYamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V., as of August 2005)1,051
进行中（未招募）
1 期
Evaluation of Efficacy and Safety of Sarilumab in Patients with GCAMedDRA version: 20.0Level: LLTClassification code 10018250Term: Giant cell arteritisSystem Organ Class: 100000004866Giant Cell ArteritisEUCTR2017-002988-18-BESanofi-Aventis Recherche & Développement508